AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Microangiopathy
Number of subjects: 327
Study 27234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerosis
Number of subjects: 327
Study 27234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with atherosclerosis
Number of subjects: 327
Study 27234509 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-PulmoBind injection for SPECT imaging in humans
Number of subjects: 19
Study 27234509 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-PulmoBind injection for SPECT imaging in supine dogs (n=5)
Number of subjects: 19
Study 27234642 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor everolimus
Number of subjects: 73
Study 27235137 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-115
Number of subjects: 8
Study 27235836 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT)
Number of subjects: 84
Study 27236150 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy (telaprevir 750 mg 8-hourly, pegylated interferon 180 µg weekly, ribavirin 600 mg daily) followed by pegylated interferon and ribavirin alone for 36 weeks.
Number of subjects: 74
Study 27236150 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy
Number of subjects: 74
Study 27236253 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-measured minimal lumen area (MLA) <2.79 mm²
Number of subjects: 103
Study 27236253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vsub/MLA(2) >4.04
Number of subjects: 103
Study 27236253 — intervention group
Group type: COMPARATOR
Intervention: IVUS-MLA
Number of subjects: 103
Study 27236390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy or in combination with non-biologic DMARDs, 8 mg/kg infused over 60 minutes every 4 weeks (up to 6 times)
Number of subjects: 28
Study 27236390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 28
Study 27237404 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access using the 'preclose' technique with the Perclose Proglide device
Number of subjects: 94
Study 27237404 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous closure
Number of subjects: 94
Study 27237404 — intervention group
Group type: COMPARATOR
Intervention: Open surgical access
Number of subjects: 94
Study 27237404 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications related to vascular access
Number of subjects: 94
Study 27237404 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 94
Study 27237429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg, once daily) plus ribavirin (1000-1200 mg/day) for 12 weeks
Number of subjects: 66
Study 27237429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 66
Study 27237786 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage (EUS-BD) using a novel algorithm based on patient anatomy
Number of subjects: 52
Study 27238065 — intervention group
Group type: COMPARATOR
Intervention: Parent training + stimulant medication + placebo (Basic)
Number of subjects: 168
Study 27238065 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training + stimulant + risperidone (Augmented)
Number of subjects: 168
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (T1: 47%, T2: 79%)
Number of subjects: 20000
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians (T1: 51%, T2: 94%)
Number of subjects: 20000
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (T1: 73%, T2: 87%)
Number of subjects: 20000
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (T1: 78%, T2: 92%)
Number of subjects: 20000
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians (T1: 94%, T2: 97%)
Number of subjects: 20000
Study 27238163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians (T1: 94%, T2: 96%)
Number of subjects: 20000
Study 27238653 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tumour shrinkage (eTS) ≥10% at first postbaseline assessment
Number of subjects: 4334
Study 27238827 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Number of subjects: 573
Study 27239317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app with health counseling
Number of subjects: 151
Study 27239317 — intervention group
Group type: COMPARATOR
Intervention: Mobile app without health counseling
Number of subjects: 151
Study 27239329 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide MMX 9 mg daily for ≤8 weeks (induction of remission)
Number of subjects: 300
Study 27239329 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose (late add-on)
Number of subjects: 300
Study 27239329 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide MMX added to mesalazine ≤2 weeks since mesalazine increased/optimised (early add-on)
Number of subjects: 300
Study 27239329 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide MMX as monotherapy (mono)
Number of subjects: 300
Study 27239324 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (2.0 g/day)
Number of subjects: 39
Study 27239324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27239503 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Memory Impairment (SMI)
Number of subjects: 5106
Study 27239503 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Memory Impairment-related worries
Number of subjects: 5106
Study 27239503 — intervention group
Group type: COMPARATOR
Intervention: SMI and related worries as predictors
Number of subjects: 5106
Study 27240885 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatments for differentiated and medullary thyroid cancers
Number of subjects: 0
Study 27240885 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (surgery followed by either radioactive iodine or observation)
Number of subjects: 0
Study 27241455 — intervention group
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Number of subjects: 5
Study 27242464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (CSR) for 7 days (4 hours time in bed, TIB)
Number of subjects: 12
Study 27242464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (CSR) for 7 days (4 hours TIB)
Number of subjects: 12
Study 27242464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery days (8 hours TIB) after CSR
Number of subjects: 12
Study 27242521 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic mild cognitive impairment (aMCI)
Number of subjects: 44
Study 27242521 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal control (NC)
Number of subjects: 44
Study 27242930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-i)
Number of subjects: 59
Study 27242930 — intervention group
Group type: COMPARATOR
Intervention: Auricular Acupuncture (AA)
Number of subjects: 59
Study 27243356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel daily disposable contact lenses (1-DAY ACUVUE MOIST)
Number of subjects: 86
Study 27244371 — intervention group
Group type: COMPARATOR
Intervention: Single BVS
Number of subjects: 236
Study 27244371 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple BVS
Number of subjects: 236
Study 27244805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulator therapy
Number of subjects: 1
Study 27244849 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers with insulin use before pregnancy (IBP)
Number of subjects: 10781
Study 27244849 — intervention group
Group type: COMPARATOR
Intervention: Infants of mothers without IDDM
Number of subjects: 10781
Study 27244882 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (100 mg/m2) on day 1, 8, 22 and 29, and cisplatin (75 mg/m2) on day 1 and 22
Number of subjects: 35
Study 27245095 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (HDAC inhibitor)
Number of subjects: 1
Study 27245295 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Antiretroviral Therapy (ART)
Number of subjects: 2387
Study 27245295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 2387
Study 27245312 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-120 (mutant IDH1 inhibitor)
Number of subjects: 3
Study 27245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Reaction Time (RT) test
Number of subjects: 16
Study 27245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control assessment
Number of subjects: 16
Study 27245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention assessment
Number of subjects: 16
Study 27245618 — intervention group
Group type: COMPARATOR
Intervention: Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)
Number of subjects: 16
Study 27245663 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR101 duplication
Number of subjects: 153
Study 27245762 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Italian EPIC Food Frequency Questionnaire (FFQ)
Number of subjects: 200
Study 27245762 — intervention group
Group type: COMPARATOR
Intervention: 7-day weighed food record
Number of subjects: 200
Study 27245833 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 107
Study 27245833 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 107
Study 27246166 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care services provided in 30 centres across 12 countries, including 24 hospitals, 4 hospices, 1 nursing home, and 1 home-care service.
Number of subjects: 1698
Study 27246166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-reported symptoms collected at baseline and monthly thereafter.
Number of subjects: 1698
Study 27246166 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up data on patient mortality.
Number of subjects: 1698
Study 27246604 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 117
Study 27246604 — intervention group
Group type: COMPARATOR
Intervention: HCV mono-infection
Number of subjects: 117
Study 27246911 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 23
Study 27247136 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib monotherapy for 2 months followed by 6 months of combination therapy with idelalisib and ofatumumab
Number of subjects: 24
Study 27247136 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib reinitiated with steroids
Number of subjects: 24
Study 27247136 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib therapy
Number of subjects: 24
Study 27247202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablets
Number of subjects: 68
Study 27247202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gel
Number of subjects: 68
Study 27247202 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable, implant, or vaginal ring
Number of subjects: 68
Study 27247202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal film or suppository
Number of subjects: 68
Study 27247324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1144
Study 27249077 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 27249077 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27249553 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT-CEUS
Number of subjects: 20
Study 27249553 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT-DCE-MRI
Number of subjects: 20
Study 27249553 — intervention group
Group type: EXPERIMENTAL
Intervention: nPTT-CEUS
Number of subjects: 20
Study 27249553 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT-CEUS and nPTT-CEUS
Number of subjects: 20
Study 27249939 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant rate of force application with varying peak force conditions.
Number of subjects: 25
Study 27251684 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 112
Study 27251684 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS)
Number of subjects: 112
Study 27251869 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct outreach (DO) recruitment approach
Number of subjects: 19354
Study 27251870 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-based recruitment
Number of subjects: 3371
Study 27251870 — intervention group
Group type: COMPARATOR
Intervention: Household-based recruitment
Number of subjects: 3371
Study 27251871 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-based sampling (PBS)
Number of subjects: 850
Study 27251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct outreach strategies (direct mail, mass media, provider referrals, social networking)
Number of subjects: 10
Study 27251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach strategies
Number of subjects: 10
Study 27251872 — intervention group
Group type: COMPARATOR
Intervention: Community characteristics
Number of subjects: 10
Study 27252072 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet campaign (online quiz competition)
Number of subjects: 6720
Study 27252072 — intervention group
Group type: COMPARATOR
Intervention: Promotional leaflets (control group)
Number of subjects: 6720
Study 27252174 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine)
Number of subjects: 45
Study 27252174 — intervention group
Group type: COMPARATOR
Intervention: External control
Number of subjects: 45
Study 27252647 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analog liraglutide
Number of subjects: 38
Study 27252647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27252787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 279
Study 27253664 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteasomal inhibition
Number of subjects: 0
Study 27253664 — intervention group
Group type: COMPARATOR
Intervention: Wild-type AIP
Number of subjects: 0
Study 27253664 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP variants
Number of subjects: 0
Study 27253988 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIT with MAT-Feld1 adsorbed to aluminum hydroxide
Number of subjects: 20
Study 27253988 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (placebo)
Number of subjects: 20
Study 27255328 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in East Asian patients with T2D
Number of subjects: 671
Study 27255328 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninsulin anti-hyperglycemic agents usage
Number of subjects: 671
Study 27255328 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin usage
Number of subjects: 671
Study 27255328 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DDS)
Number of subjects: 671
Study 27255499 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 20
Study 27255678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg (dose level 1)
Number of subjects: 9
Study 27255678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg (dose level 2)
Number of subjects: 9
Study 27255774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial implantation of stromal vascular fraction (SVF)
Number of subjects: 28
Study 27256085 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-attributable GP episodes
Number of subjects: 450158
Study 27256085 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-attributable hospitalisations
Number of subjects: 450158
Study 27256085 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-attributable deaths
Number of subjects: 450158
Study 27256085 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-attributable GP episodes for otitis media
Number of subjects: 450158
Study 27256085 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-attributable antibiotic prescriptions
Number of subjects: 450158
Study 27256085 — intervention group
Group type: COMPARATOR
Intervention: Comparison with influenza
Number of subjects: 450158
Study 27256597 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual biofeedback (AV)
Number of subjects: 10
Study 27256597 — intervention group
Group type: COMPARATOR
Intervention: Free breathing (FB)
Number of subjects: 10
Study 27256670 — intervention group
Group type: EXPERIMENTAL
Intervention: SB623 (modified bone marrow-derived mesenchymal stem cells)
Number of subjects: 18
Study 27256708 — intervention group
Group type: EXPERIMENTAL
Intervention: Height adjustable desk intervention for 12 months
Number of subjects: 0
Study 27256708 — intervention group
Group type: COMPARATOR
Intervention: Sitting posture
Number of subjects: 0
Study 27256874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib (sorafenib 400 mg p.o. b.i.d. and lenalidomide 15 mg p.o. daily, with planned dose escalation)
Number of subjects: 5
Study 27256874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib
Number of subjects: 5
Study 27257978 — intervention group
Group type: EXPERIMENTAL
Intervention: REP 2055 monotherapy
Number of subjects: 20
Study 27257978 — intervention group
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca monotherapy
Number of subjects: 20
Study 27257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with pegylated interferon alpha 2a or thymosin alpha 1
Number of subjects: 20
Study 27257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after REP 102 study
Number of subjects: 20
Study 27258098 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cells from obese participants with metabolic abnormalities (OMA+)
Number of subjects: 9
Study 27258098 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study 27258098 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial period after high-fat meal
Number of subjects: 9
Study 27258399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mobile testing (2-week multidisease community health campaign followed by home-based testing)
Number of subjects: 116326
Study 27258399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mobile testing
Number of subjects: 116326
Study 27258476 — intervention group
Group type: EXPERIMENTAL
Intervention: activ C disc prosthesis
Number of subjects: 200
Study 27258647 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (two doses, eight weeks apart)
Number of subjects: 100
Study 27258647 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 (one dose)
Number of subjects: 100
Study 27258647 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 100
Study 27259804 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency of vegetables intake
Number of subjects: 1903
Study 27259804 — intervention group
Group type: COMPARATOR
Intervention: Low frequency of vegetables intake
Number of subjects: 1903
Study 27260009 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV; Rotarix™, GSK Vaccines)
Number of subjects: 1348
Study 27260009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348
Study 27260636 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% L-menthol applied simultaneously with 10% CA
Number of subjects: 14
Study 27260636 — intervention group
Group type: COMPARATOR
Intervention: 10% CA alone
Number of subjects: 14
Study 27261237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 0
Study 27261237 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor concentrate
Number of subjects: 0
Study 27261237 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0
Study 27261237 — intervention group
Group type: COMPARATOR
Intervention: Ecallantide
Number of subjects: 0
Study 27261467 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg orally once daily three times per week
Number of subjects: 15
Study 27261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Number of subjects: 0
Study 27261549 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 200
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Early uNGAL excretion
Number of subjects: 200
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative outcome
Number of subjects: 200
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in serum creatinine >50%
Number of subjects: 200
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliguria (urine output <0.5 ml kg(-1) h(-1))
Number of subjects: 200
Study 27262736 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 200
Study 27262861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 470
Study 27262861 — intervention group
Group type: COMPARATOR
Intervention: Metallic everolimus-eluting stent (EES)
Number of subjects: 470
Study 27262861 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural asymmetry index (AI) >0.30
Number of subjects: 470
Study 27265450 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 242
Study 27265450 — intervention group
Group type: COMPARATOR
Intervention: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 242
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation index
Number of subjects: 488
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Number of subjects: 488
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 488
Study 27266507 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 488